2010
DOI: 10.3324/haematol.2010.030148
|View full text |Cite
|
Sign up to set email alerts
|

Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
24
0

Year Published

2011
2011
2017
2017

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(25 citation statements)
references
References 28 publications
1
24
0
Order By: Relevance
“…Today, maternally administered IVIG is generally considered to be highly successful in preventing ICH, the true goal of antenatal management, even when failing to keep the fetal platelet count within a safe range. In keeping with previous studies (Vinogard & Bussel, 2010;Kamphuis & Oepkes, 2011;van der Lugt et al, 2015), the response rate to IVIG in our study was only 50%, when defined as neonatal platelet counts remaining <50 9 10 9 /l. Furthermore, two of these non-responders were diagnosed with ICH, a finding also reported before (Berkowitz et al, 2006).…”
Section: Discussionsupporting
confidence: 67%
See 1 more Smart Citation
“…Today, maternally administered IVIG is generally considered to be highly successful in preventing ICH, the true goal of antenatal management, even when failing to keep the fetal platelet count within a safe range. In keeping with previous studies (Vinogard & Bussel, 2010;Kamphuis & Oepkes, 2011;van der Lugt et al, 2015), the response rate to IVIG in our study was only 50%, when defined as neonatal platelet counts remaining <50 9 10 9 /l. Furthermore, two of these non-responders were diagnosed with ICH, a finding also reported before (Berkowitz et al, 2006).…”
Section: Discussionsupporting
confidence: 67%
“…Non-or minimal-invasive strategies with maternally administrated intravenous gammaglobulin (IVIG) are regarded as the primary management option although a substantial proportion of fetuses (up to 55%) seem not to respond to IVIG treatment, with platelet counts remaining below 50 9 10 9 /l (Vinogard & Bussel, 2010;Kamphuis & Oepkes, 2011;van der Lugt et al, 2015). On the other hand, current laboratory techniques may miss some clinically evident cases, leaving the subsequent pregnancies without required therapy (Bussel et al, 2005).…”
Section: Fetal and Neonatal Alloimmune Thrombocytopenia (Fnait)mentioning
confidence: 99%
“…8,15,16 These treatments are expensive, limited by access to IVIg, and not without side effects, and therefore some authors recommend the use of a stratified treatment approach based on the severity of previously affected pregnancies (the only clear predictor of disease severity). [16][17][18] Although the rate of fetal ICH in pregnancies undergoing immunomodulatory treatment appears low, it is clear that this is not accompanied by a consistent rise in platelet count in the fetus. 19,20 It may be that IVIg somehow lessens the risk of bleeding even in the absence of a rise in platelet count but it is also possible that the reduction of ICH comes with the increased care provided to the pregnant woman.…”
Section: Introductionmentioning
confidence: 99%
“…About 20% of the newborns remain severely thrombocytopenic despite treatment of the mother with intravenous immunoglobulin and steroids. 12,17 Submitted November 20, 2012; accepted April 26, 2013. Prepublished online as Blood First Edition paper, May 3, 2013; DOI 10.1182/blood-2012-11-468561.…”
Section: Introductionmentioning
confidence: 99%